July 2021. Volume 17. Number 2

Evinacumab seems to be safe and effective in homozygous familial hypercholesterolemia

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-20.

Reviewers: Molina Arias M1, Martín Masot R2.
1Servicio de Gastroenterología. Hospital Universitario La Paz. Madrid. España.
2UGC Pediatría. Hospital Regional Universitario de Málaga. Málaga. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 15/03/2021
Acceptance date: 07/04/2021
Publication date: 14/04/2021

Abstract

Authors’ conclusions: in patients older than 12 years with homozygous familial hypercholesterolemia, the use of evinacumab compared with placebo resulted in a reduction of LDL cholesterol levels at 24 weeks.

Reviewers’ commentary: treatment with evinacumab appears to be a safe and effective adjunct to the usual treatment of patients with homozygous familial hypercholesterolemia.

How to cite this article

Molina Arias M, Martín Masot R. Evinacumab parece seguro y eficaz en el tratamiento de la hipercolesterolemia familiar homocigota. Evid Pediatr. 2020;17:16.

AVC | Critically appraised articles

Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711-20.

Reviewers: Molina Arias M1, Martín Masot R2.
1Servicio de Gastroenterología. Hospital Universitario La Paz. Madrid. España.
2UGC Pediatría. Hospital Regional Universitario de Málaga. Málaga. España.
Correspondence: Manuel Molina Arias. Email: mma1961@gmail.com
Reception date: 15/03/2021
Acceptance date: 07/04/2021
Publication date: 14/04/2021

How to cite this article

Molina Arias M, Martín Masot R. Evinacumab parece seguro y eficaz en el tratamiento de la hipercolesterolemia familiar homocigota. Evid Pediatr. 2020;17:16.

14/04/2021

Linked Comment